Enrolling by invitationPhase 3NCT05667493
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Studying Amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Intervention
- Eplontersen(drug)
- Enrollment
- 1400 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- Mayo Clinic, Scottsdale, Arizona, United States
- Cedars-Sinai Medical Center, Beverly Hills, California, United States
- Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California, United States
- University Of California San Francisco Urology Practice, San Francisco, California, United States
- Stanford University (Leland Stanford Junior University), Stanford, California, United States
- University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States
- MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion, Washington D.C., District of Columbia, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- Piedmont Heart of Fayetteville, Atlanta, Georgia, United States
- Emory Heart and Vascular Center - Emory Clifton Campus, Atlanta, Georgia, United States
- Piedmont Atlanta Hospital, Fayetteville, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Indiana University Health University Hospital, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05667493 on ClinicalTrials.govOther trials for Amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07560306[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyBrigham and Women's Hospital
- RECRUITINGNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer
- RECRUITINGPHASE2NCT07285044The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasMayo Clinic
- RECRUITINGNCT07218705A Study Of MCG In Cardiac AmyloidosisMayo Clinic
- ENROLLING BY INVITATIONPHASE2NCT06723015Tau PET Outcomes With Anti-amyloid ImmunotherapiesMayo Clinic
- RECRUITINGNCT07213297Comprehensive Program for Hereditary Transthyretin AmyloidosisHospital de Alta Complejidad en Red
- RECRUITINGPHASE1NCT06790394Test-retest Study With [18F]FBB in Cardiac AmyloidosisLife Molecular Imaging GmbH
- RECRUITINGNANCT07112066Multimodality Cardiac Imaging for Disease Progression in ATTR-CMDominik Benz